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Abstract: Protein accumulation has been identiﬁed as a characteristic of many degenerative conditions,
such as neurodegenerative diseases and aging. In most cases, these conditions also present with
diminished protein degradation. The ubiquitin-proteasome system (UPS) is responsible for the
degradation of the majority of proteins in cells; however, the activity of the proteasome is reduced
in these disease states, contributing to the accumulation of toxic protein. It has been hypothesized
that proteasome activity, both ubiquitin-dependent and -independent, can be chemically stimulated
to reduce the load of protein in diseased cells. Several methods exist to identify and characterize
stimulators of proteasome activity. In this review, we detail the ways in which protease activity can
be enhanced and analyze the biochemical and cellular methods of identifying stimulators of both the
ubiquitin-dependent and -independent proteasome activities.
Keywords: proteasome; stimulation; ﬂuorescent probes; 20S CP

1. Introduction
One of the most basic, essential cellular processes is the degradation of proteins. This primarily
occurs through two pathways: degradation by lysosomes, also known as autophagy, or degradation by
the proteasome [1,2]. The proteasome degrades proteins using two systems, the ubiquitin-dependent
(UPS) and the ubiquitin-independent (UIPS) proteasome systems, Figure 1A [3,4]. The UPS utilizes
the 26S proteasome isoform, which is comprised of a 19S regulatory particle (19S RP) and a 20S
core particle (20S CP). The 19S RP is responsible for recognizing a ubiquitinated substrate, removing
ubiquitin, unfolding the substrate, and shuttling it into the 20S CP. The physical association of the
19S RP to the 20S CP causes a conformational change in the α-ring of the 20S CP to allow the protein
substrate to enter for hydrolysis [5]. The 20S CP is composed of four heptameric rings in the order
α, β, β, α. The α-subunits form the gate of the 20S CP, which prevents well-folded proteins from
entering the hydrolysis chamber of the 20S CP without a regulatory particle present [6]. The β-rings
of the 20S CP each house three catalytic subunits, β1, β2, and β5, which correspond to the following
hydrolysis activities: caspase-like, trypsin-like, and chymotrypsin-like, respectively. The UPS requires
a system of proteins to polyubiquitinate substrates that are recognized and degraded by the 26S
proteasome. A well-characterized pathway in which the UPS plays a critical role is the endoplasmic
reticulum-associated protein degradation (ERAD) system [7,8]. ERAD focuses on the degradation of
misfolded proteins, and many disease states characterized by ER stress are correlated with a decrease in
UPS activity [9,10]. The UIPS, on the other hand, cannot degrade ubiquitinated substrates. This system
utilizes the 20S CP for the degradation of intrinsically disordered or oxidatively damaged proteins that
become unfolded [11,12]. These proteins are capable of entering the gate of the 20S CP without the
presence of the 19S RP to initiate a conformational change of the α-ring. However, the UIPS can make

Molecules 2019, 24, 2341; doi:10.3390/molecules24122341

www.mdpi.com/journal/molecules

Molecules 2019, 24, 2341

2 of 14

use of other regulatory particles, such as the 11S RP, which can cause a similar conformational change
of the α-ring to expedite substrate entry [13].
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Figure 1. (A) Overview of the ubiquitin-proteasome system (UPS) and the ubiquitin-independent
proteasome system (UIPS). The UPS utilizes a set of E-ligases to polyubiquitinate protein substrates for
recognition and degradation by the 26S proteasome. The UIPS employs the 20S core particles (20S CP),
which can be capped or uncapped by the 11S regulatory particle (11S RP), to degrade oxidatively
damaged and intrinsically disordered proteins. (B) In the presence of pro-inﬂammatory signals, such as
interferon-gamma (IFN-γ), the catalytic subunits of the standard 20S CP (sCP) can become exchanged
for the catalytic subunits of the immunoproteasome (iCP).

In healthy cells, the UPS and UIPS are both working to help alleviate the load of damaged proteins
or proteins that have served their purpose and need to be degraded. In healthy, young ﬁbroblasts,
the 26S proteasome isoform only accounts for approximately 21 to 35% of proteasome isoforms in
the cell [14]. The remaining percentage is comprised of the 11S RP-capped 20S CP and free 20S CP,
which is the primary isoform, accounting for two-thirds of the proteasome population. In immune
cells and cells exposed to pro-inﬂammatory signals, the standard 20S CP can become exchanged for the
immunoproteasome, Figure 1B [15]. The immunoproteasome is structurally identical to the standard
20S CP, except for the catalytic subunits, which are exchanged for the β1i, β2i, and β5i [16]. These
subunits have diﬀerent hydrolysis activities than the standard 20S CP, resulting in alternative cleavage
sites of protein substrates. The immunoproteasome produces peptides capable of being loaded into
MHC-I complexes to alert the immune system of an infection.
Many disease states have been characterized by an accumulation of protein, leading to
proteotoxicity. Diseases, such as Alzheimer’s, Parkinson’s, aging, Huntington’s, and amyotrophic
lateral sclerosis, exhibit a diminished ability of cells to maintain proper proteostasis [17–23]. This is due,
in part, to reduced activity of the proteasome. In the majority of these diseases, this phenomenon is the
result of a lack of expression of subunits composing the 19S RP, increasing the amount of free 20S CP, or
both the 19S RP and 20S CP, decreasing the total quantity of proteasomes in the cell [24]. Because this
is a shared characteristic of many disease states, developing a method to enhance proteasome activity,
either 26S or 20S CP, to reduce protein accumulation has become a prominent area of research. Multiple
studies have found that increased proteasome activity is beneﬁcial, decreasing the accumulation of
oxidized protein and delaying aging [25–27]. Enhancing proteasome activity can be accomplished
through genetic manipulation of subunit expression, such as overexpressing the β5 subunit of the 20S
CP or Rpn-6 of the 19S RP, or through peptide or small molecule stimulation [26,28–30]. Chemical
stimulators are commonly grouped into two categories: gate-openers, which modulate the α-ring
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of the 20S CP to enhance substrate entry, and allosteric modulators of the hydrolysis activity, which
can impact at least one of the activities performed by the catalytic β-subunits. Several peptides or
small molecule stimulators of the proteasome have been identiﬁed by a few diﬀerent research groups,
and the methodology to detect and characterize proteasome stimulators is an evolving ﬁeld [31–43].
In this review, we describe and assess various current techniques used to discover and evaluate small
molecule stimulators of the proteasome.
2. Discovery: Biochemical High-Throughput Screening Assays
Initial eﬀorts to discover proteasome stimulators are often performed using high-throughput
biochemical screens. These methods use puriﬁed proteasome and monitor proteasome activity through
co-incubation with a substrate (Figure 2A–C). In this section, we will review the diﬀerent techniques
used to monitor proteasome activity and describe how these methods can also be used to extrapolate a
general mechanism of stimulation of a “hit” molecule.
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Figure 2. Summary of the biochemical methods often used to identify proteasome stimulators.
(A) Fluorogenic substrates produce a ﬂuorescent signal following substrate hydrolysis. (B) Analysis
of the degradation of peptide substrates can be performed using mass spectrometry. The ﬁrst peak
in the spectra corresponds to the full peptide. The second peak corresponds to the degradation
product containing the fmoc protecting group. (C) Evaluating degradation of a speciﬁc protein by the
proteasome can be performed using SDS-PAGE analysis.

2.1. Fluorogenic Peptide Substrates
Since the discovery of the proteasome in 1983, ﬂuorogenic peptide substrates have been used to
monitor its activity. In the initial discovery, Wilk and Orlowski used peptides’ three amino acids in
length containing either a p-nitroanilide (pNA) or a 2-napthylamide (2NA) on the C-terminus [44].
The peptides used were speciﬁc to the three protease activities exhibited by the proteasome. Following
the cleavage after the third amino acid residue, the pNA or 2NA group would ﬂuoresce. Monitoring
this ﬂuorescence over time allows one to assess proteasome activity. Since 1983, many more ﬂuorogenic
peptide substrates have been synthesized for each of the activities of the proteasome [45]. The most
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commonly used employ a 7-amino-4-methylcoumarin (AMC) group on the C-terminus. This group has
a higher degree of ﬂuorescence over pNA or 2NA and therefore, provides a more eﬀective readout [46].
Table 1 lists the ﬂuorogenic peptide substrates commonly used today and the corresponding hydrolysis
activity of the proteasome.
Table 1. Common ﬂuorogenic peptide substrates used to assess proteasome activity.
Commonly Used Fluorogenic Peptide Substrates

Subunit speciﬁc cleavage

β1

Z-LLE-NA
Z-LLE-AMC
Ac-nLPnLD-AMC

β2

Boc-LRR-AMC
Z-ARR-AMC
Bz-VGR-AMC

β5

Suc-LLVY-AMC
Z-GGL-AMC
Suc-AAF-AMC

Non-speciﬁc cleavage

FRET reporter

The majority of these substrates are small (3–4 amino acids in length) and can easily ﬁt past
the gate of the 20S CP to be hydrolyzed, allowing for eﬃcient measurement of activity. Multiple
studies that have identiﬁed proteasome stimulators have utilized Suc-LLVY-AMC [32,34–36,38–41].
By plotting the change in ﬂuorescence of AMC over time, one can obtain a “rate” of hydrolysis. This
“rate” is used to compare a sample containing a tested small molecule to a control sample to determine
if there is an increase or decrease in activity. Small molecules and peptides discovered as stimulators of
the proteasome using this method are shown in Figure 3A.
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Figure 3. (A) Structures of small molecule and peptide stimulators discovered using Suc-LLVY-AMC
to monitor proteasome activity. All except betulinic acid are believed to act as gate-openers of the 20S
CP. Betulinic acid has been shown to enhance only the chymotrypsin-like activity of the β5 subunit.
(B) Structures of small molecules determined to be proteasome stimulators using the ﬂuorescence
resonance energy transfer (FRET) reporter. All except the triazine derivative are gate-openers of the
20S CP. The triazine derivative enhances a β-subunit catalytic activity, although the precise subunit
is unknown.
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A more recently developed reporter of proteasome activity utilizes ﬂuorescence resonance energy
transfer (FRET) technology to produce a ﬂuorescent signal [33]. This reporter is larger than the
commonly used AMC reporters and contains the FRET pair, Edans and Dabcyl. While the peptide
is intact, FRET occurs between the pair, producing only a minimal ﬂuorescent signal that does not
change over time. However, once the peptide is hydrolyzed, the distance between the FRET pair
increases, producing a much greater ﬂuorescent signal. Similar to the AMC reporters, this signal can be
monitored over time to assess proteasome activity. This reporter is not speciﬁc to any of the hydrolysis
activities of the proteasome and was developed to be similar to a protein-like substrate. Due to its
size, it does not easily ﬁt into the hydrolysis chamber of the 20S CP. Characterization of this reporter
revealed that it is more sensitive to 20S CP stimulation than the Suc-LLVY-AMC substrate. Figure 3B
shows the stimulating small molecules discovered using the FRET reporter [33,42].
2.2. Mass Spectrometry Substrate Analysis
Another eﬀective method for identifying stimulators of proteasome activity involves the use of
mass spectrometry (Figure 2B). First developed by Trader et al., this method employs an N-terminally
Fmoc-protected peptide substrate that is incubated with or without the proteasome for a certain
period of time [34]. The sample is then quenched and run on a mass spectrometer to identify and
quantitate the full peptide and the cleavage product(s). This provides the basal level of activity of
the proteasome. If a small molecule is included in the incubation for testing, quantitation of the full
peptide and cleavage product(s) from the chromatogram can reveal whether this molecule has any
eﬀect on proteasome activity. For this assay, the Fmoc group is kept on the N-terminus of the substrate
to facilitate retention of the peptide on the reverse-phase column. This allows for the full peptide
and the cleavage product containing the N-terminus to be easily identiﬁed and quantiﬁed on the
chromatogram. For normalization, results between samples are compared by assessing the ratio of
cleaved product to the whole peptide. This value was used to compare samples and determine the
extent of increased proteasome activity induced by a small molecule.
2.3. Gel-Based Assays
The methods described to this point utilize peptide substrates to assess proteasome activity.
Many times, small molecule enhanced degradation of a peptide substrate does not directly translate
to enhanced degradation of a protein. Gel-based assays have been developed to monitor protein
substrate degradation by the proteasome (Figure 2C) [32–35]. These assays utilize puriﬁed proteins,
both proteasome and substrate. The protein substrate is incubated (1) by itself, (2) with the proteasome,
and (3) with the proteasome and a small molecule. The samples are then run on an SDS-PAGE gel and
can either be stained with Coommassie, or an immunoblot can be performed to visualize the protein
substrate. Imaging and subsequent quantitative analysis are then performed to determine how much
of the substrate is degraded by the proteasome in the absence and presence of the small molecule.
It is important to obtain a standard curve of the protein substrate before performing this assay to
indicate the limit of detection of that particular substrate when used for an immunoblot or stained with
Coommassie. The amount of proteasome used will also need to be optimized to prevent the presence
of the proteasome from interfering with substrate quantitation of a Coommassie-stained gel. This
assay is useful to determine how much more of a particular protein can be degraded in the presence of
a small molecule stimulator, but it can also be used to assess a rate of degradation if performed for
diﬀerent time periods. Kinetic analysis using this assay can be a very beneﬁcial characterization of a
small molecule stimulator of the proteasome.
2.4. General Mechanism of Small Molecule Stimulators
All of the assays described above can be used as primary or secondary screening to either identify
or validate a small molecule stimulator of the proteasome (any isoform). Because these assays can
be used with either the 20S CP, the 26S proteasome, or the immunoproteasome, repeating the assay
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with the other isoforms can provide an indication of the mechanism of stimulation. In theory, small
molecule stimulators can act through two separate mechanisms: (1) gate-openers, which stabilize a
more gate-opened state of the 20S CP (or iCP), or (2) an allosteric modulator, impacting at least one of
the hydrolysis activities [33]. Gate-opening small molecules should not have any eﬀect on the activity of
the 26S proteasome, as the gate is occupied by the 19S RP. These types of stimulators should, however,
still maintain a stimulatory eﬀect with the immunoproteasome, which has a gate structurally identical
to that of the 20S CP. A molecule that is able to directly impact one of the hydrolysis activities will also
have this eﬀect on the 26S proteasome but will likely not aﬀect the immunoproteasome. Because the
immunoproteasome contains diﬀerent catalytic subunits, an allosteric modulator of β1, β2, or β5 of
the 20S CP should not impact β1i, β2i, or β5i of the immunoproteasome. However, these subunits
maintain a high percentage of structural similarity, so an impact on activity may still be observed [16].
Of the two general mechanisms, allosteric modulators are less common and less understood.
There is evidence that some allosteric modulators may have diﬀerent impacts on the various hydrolysis
activities. For instance, Ritonavir, a known human immunodeﬁciency virus-1 protease inhibitor,
was shown to inhibit the chymotrypsin-like activity while enhancing the trypsin-like activity of the
proteasome [47,48]. This type of impact could indicate multiple binding sites; however, further
structural studies are necessary to understand the mechanism behind this allosteric modulator.
3. Discovery: In Vitro Assays
Following the identiﬁcation and validation of small molecule proteasome stimulators, cellular
assays are often performed to determine the eﬃcacy of these stimulators in a cell model. Such assays
provide information on cell permeability and target speciﬁcity, both of which are important for a
potential therapeutic approach and for understanding the overall impacts of stimulating the proteasome.
In this section, we review the cellular assays most commonly used to assess proteasome stimulators
and discuss assays that have been used to monitor proteasome activity, which could be used to
evaluate stimulators.
3.1. GFP-Fusion Protein Assay: 20S CP Stimulator
Stimulators of the 20S CP are often examined using a green ﬂuorescent protein (GFP)-fusion
protein (Figure 4) [32,34,35]. Cell lines suitable for transfection are transfected to express a known
substrate of the 20S CP that has been fused to GFP. Common protein substrates include α-synuclein,
tau, and ornithine decarboxylase. This assay is eﬀective at monitoring 20S CP-mediated degradation,
as the uncapped 20S CP can degrade the unstructured portion of the GFP-protein fusion, leaving
an increased amount of free, intact GFP, whereas the 26S proteasome can degrade the entire fusion
protein. The transfected cells can be treated with a 20S CP stimulator to be compared to a control
sample. The time of treatment is dependent on the toxicity of the molecule; however, most studies
using this assay are performed using a 24-hr treatment period. Following treatment, the cells are lysed,
and a Western blot is performed, looking speciﬁcally at GFP. The analysis is performed by quantitating
the bands corresponding to the fusion protein and free GFP. The ratio of free GFP to the fusion is
calculated for the treated sample and compared to the control to determine the increased activity of the
20S CP. One of the necessary assumptions of this assay is that the activity of the 26S proteasome is
consistent across all samples. Because the 26S proteasome will degrade the entire fusion protein and
the free GFP that is produced by 20S CP activity, it is important that the activity of the 26S proteasome
is the same across all samples. This assay can eﬀectively be used once it is determined that the small
molecule does not impact 26S proteasome activity.
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Figure 4. General procedure of evaluating a 20S CP stimulator in cells using a GFP-α-synuclein
fusion protein.

3.2. Analysis of Endogenous Protein Levels
Evaluating the impact of a proteasome stimulator on the degradation of an endogenous protein can
often be diﬃcult to assess due to ongoing protein synthesis. To more easily detect enhanced degradation,
many studies have employed cycloheximide, a protein synthesis inhibitor [49]. Cycloheximide exerts
its eﬀects by inhibiting translational elongation in eukaryotes, making it a useful tool to evaluate
the degradation of proteins. Often, cycloheximide is used to determine the half-life of a particular
protein [50]. This is accomplished by treating cells with cycloheximide for various time periods and
performing a Western blot for that protein to see at what point the band disappears. Cycloheximide
is the most commonly used agent for these purposes; however, protein synthesis inhibition by
cycloheximide is not 100% eﬃcient. The transcription inhibitor α-amanitin is a potent protein synthesis
inhibitor and can be used as a substitute [51].
When using cycloheximide, or any protein synthesis inhibitor, to evaluate a proteasome stimulator,
the endogenous protein of interest is often one that is already known to be degraded by at least
one isoform of the proteasome. For example, α-synuclein is a known substrate of the 20S CP and is
commonly used to evaluate the impact of a 20S CP stimulator in neuronal cells [34]. When performing
an experiment to look at endogenous protein, it is important to understand which isoforms of the
proteasome will be impacted. This can be done using the biochemical assays mentioned above.
To analyze stimulators of the 26S proteasome, it can be beneﬁcial to look at the ubiquitinated form of
the protein of interest. Substrates of the 26S proteasome are polyubiquitinated for recognition by the
19S RP [52]. Therefore, it can be helpful to analyze the ubiquitinated protein levels when evaluating
protein degradation by the 26S proteasome. Analysis of endogenous protein levels can be performed
by Western blot.
4. Methods to Monitor Proteasome Activity in Cells
4.1. GFP-Fusion Protein Assay: 26S Proteasome Stimulator
GFP-fusion proteins have also been speciﬁcally designed to monitor 26S proteasome
activity [53–56]. These proteins are typically used to analyze overall UPS activity or to evaluate
inhibitors of the 26S proteasome. However, these GFP-constructs may also have the potential to be
used as tools to measure 26S proteasome stimulation in cells using small molecules. The most eﬀective
constructs for this purpose would be the GFPU construct, which is GFP fused to a sixteen amino
acid CL1 degron, or the UbV-GFP fusion, which contains a mutated, non-cleavable ubiquitin fused to
GFP [53,55]. The presence of the degron in GFPU enhances the recognition and degradation of this
protein in cells. A similar phenomenon occurs with the UbV-GFP protein, as the presence of ubiquitin
induces polyubiquitination and causes more eﬃcient degradation. These proteins could be used in
a kinetic ﬂuorescence assay to monitor the decrease in GFP ﬂuorescence over time. In the presence
of a 26S proteasome stimulator, it would be expected that GFP signal would decrease at a faster rate.
However, these proteins may be degraded too quickly by the non-stimulated 26S proteasome to be
adequately used in this context, requiring the use of a more stable construct.
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For a longer study that would involve cell treatment with a stimulator for several hours, a GFP
fusion that is less susceptible to degradation would be required. GFP is naturally a very stable protein
and is not an eﬃcient substrate of the UPS [53]. Therefore, GFP mutants have been created that are not
as stable as native GFP, yet still have a longer half-life than the proteins mentioned above. One such
fusion would be Ub-L-GFP, which utilizes the N-end rule to prevent quick degradation of GFP, yet is
not as stable as the native M-GFP.53 The N-end rule suggests that having an arginine or an amino acid
residue that is readily acetylated as the N-terminal residue enhances the recognition and degradation
of that protein [57]. By replacing the methionine with a leucine as the N-terminal residue, GFP becomes
destabilized and is more readily degraded by the UPS. This fusion protein could be a useful tool for
the analysis of a 26S proteasome stimulator to determine enhanced degradation of Ub-L-GFP when the
stimulator is present.
4.2. Radioactively Labeled Proteasome Substrates
One of the ways in which researchers study the rate of protein degradation by the proteasome is to
use a radioactively labeled amino acid, such as [H3] phenylalanine ([H3]-Phe) [58]. By exposing cells to
[H3]-Phe, this amino acid becomes incorporated into proteins. Varying the length of exposure allows
for the monitoring of short-lived or long-lived proteins. The labeled proteins will then be degraded by
either the proteasome or the lysosome, producing short peptides that are further degraded by other
proteases into individual amino acids. The cells are then incubated with a large excess of non-labeled
Phe to prevent reincorporation of the labeled amino acids into newly synthesized proteins. This also
encourages the excretion of the labeled amino acids into the medium, as the non-labeled Phe is taken
into the cells. For the evaluation of short-lived proteins, cycloheximide is included in the medium
supplemented with the non-labeled Phe to prevent protein synthesis and allow for immediate analysis
without a long incubation time. Following incubation with the non-labeled amino acid, aliquots of the
medium can be taken at diﬀerent time periods. The medium should contain the degradation products
of proteins that have been excreted from the cell. To ensure that only degradation products are present,
trichloroacetic acid (TCA) is added to the medium to precipitate any proteins. This solution can then
be centrifuged to separate the precipitated proteins from the degradation products, which will remain
in the supernatant. Once the aliquots of the medium have been removed from the plate, the cells
can be dissolved in a solution of NaOH. Both the supernatants containing the degradation products
from various time periods and the cell lysate containing the labeled proteins are placed into separate
scintillation vials. By measuring the amount of [H3]-Phe in each sample, one can determine the rate
of total protein degradation. Performing an additional experiment of dosing with a proteasome or
autophagy inhibitor allows for the calculation of how much protein degradation is due to each pathway.
This method of analyzing proteasome activity has not been applied to a small molecule proteasome
stimulator. However, such an experiment would provide information other assays fail to deliver.
The method described above provides a proteasomal rate of degradation of cellular proteins, which
is precisely what is impacted by a small molecule stimulator. Therefore, this assay could provide
information pertaining to how the rate of protein degradation by the proteasome is aﬀected by a small
molecule stimulator in cells. Unfortunately, there is no way to diﬀerentiate degradation by the 26S
proteasome versus the 20S CP, as the majority of proteasome inhibitors directly target the 20S CP.
KDT-11 and RA-190 are known inhibitors of Rpn13, which is a ubiquitin-receptor of the 19S RP [59,60].
These inhibitors could potentially be used as a control to identify how much protein degradation is
ubiquitin-independent. In addition, the majority of the proteins degraded by the 20S CP are known to
be short-lived proteins, such as regulatory and signaling proteins [6,61]. Performing this experiment
with a 20S CP stimulator to monitor short-lived proteins could provide a diﬀerence in the rate of
degradation of these proteins. However, further experimentation is needed to determine whether this
method could be useful in analyzing a stimulator of the 20S CP.
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4.3. In Vitro Fluorogenic and Bioluminescent Reporters
A few ﬂuorogenic reporters have been developed to measure proteasome activity in cells,
corresponding to the hydrolysis of the reporter [62,63]. One such reporter is referred to as the
TED peptide, which stands for Tat-Edans-Dabcyl (Figure 5A) [62]. Ten amino acids from the
transfer domain of the Tat protein were added to the C-terminus of this reporter to help with
cell permeability [64]. The amino acid sequence between the FRET pair, Edans-Dabcyl, contains the
LLVY cleavage-determining motif, with the intention of achieving speciﬁcity for the β-5 subunit of
the 20S CP. Further lysine residues were added to the N-terminus of the peptide to ensure a net
positive charge and promote membrane penetration. Analysis of this reporter revealed that the primary
cleavage site is following the tyrosine; however, other cleavage products are also produced. Incubating
the TED peptide with various cell lines produced an increase in ﬂuorescence of Edans, associated with
cleavage of the peptide by the proteasome. A maximum ﬂuorescence signal was observed after 15 min
of incubation.
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Figure 5. Structures of two ﬂuorogenic reporters of proteasome activity that are eﬀective in cells:
(A) the Tat-Edans-Dabcyl (TED) peptide and (B) TBZ-1.

Another reporter, TBZ1, published recently by Zerfas et al. is eﬀective at selectively monitoring
immunoproteasome activity in cells (Figure 5B) [63]. This reporter utilizes a rhodamine moiety for its
source of ﬂuorescence, following reporter hydrolysis, and a peptoid portion to increase cell permeability.
Both TBZ1 and the TED peptide are able to monitor proteasome activity in cells in a kinetic ﬂuorescence
assay. Though these methods have not been applied to stimulators of any isoform of the proteasome,
each oﬀers an opportunity to directly monitor enhanced proteasomal activity in cells in the presence of
a small molecule stimulator.
In addition to these ﬂuorogenic reporters, a similar way of assessing proteasome activity utilizes
bioluminescent reporters [65]. These reporters are structurally based on the AMC ﬂuorogenic reporters
often used in biochemical assays to monitor the individual activities of the proteasome. Instead of
having an AMC group on the C-terminus, this group is substituted for aminoluciferin, which can
be utilized by luciferase to produce light. The amount of light produced is directly proportional
to proteasome activity. These luminescent substrates can aptly measure the individual proteasome
activities in cells, oﬀering a unique tool to assess proteasome stimulators.
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5. Structural Evaluation of Small Molecule Stimulators of the Proteasome
5.1. AFM
Atomic force microscopy (AFM) has been proven an eﬀective method of identifying the various
states of the 20S CP [66,67]. The gate of the 20S CP is formed by the N-termini of several α-subunits.
In solution, the gate is able to ﬂux between the open- and closed-state, with the majority of the 20S CP in
the closed-state. AFM is able to determine the percentage of 20S CP in the open-or closed-state. Several
small molecule stimulators of the 20S CP are believed to stabilize the open-gate conformation, which
would increase the percentage of 20S CP in this state. Using AFM, several studies have been able to
conﬁrm the conformational changes associated with the binding of a small molecule stimulator [35,43].
In particular, the small molecule TCH-165 discovered by Njomen et al. was determined to increase the
percentage of open-state 20S CP from 28% ± 4% in the control sample to 59% ± 3% in the presence of
2 µM TCH-165 [35]. AFM has been shown to distinguish between these states of the 20S CP; however,
the resolution using this technique is not high enough to determine speciﬁc structural elements. To look
at amino acid structure and small molecule binding, a higher resolution technique, such as cryo-electron
microscopy (cryo-EM), needs to be used.
5.2. Cryo-EM
Cryo-EM has been successfully used to determine the structure of the human 20S CP and the 26S
proteasome in diﬀerent conformational states, Figure 6 [68,69]. Using this technique to analyze the
binding site of a small molecule stimulator can illuminate the binding pocket and the key amino acids
necessary for binding. Cryo-EM can also identify structural conformational changes that occur as a
result of small molecule binding. This information is important to understand what subunits can be
impacted to inﬂuence proteasomal activity. Identifying the binding pocket and key interactions can
lead to structure-activity-relationship (SAR) studies that modify the structure of the small molecule to
better interact with the proteasome.

Figure 6. Cryo-EM structure of the human singly-capped 26S proteasome.

6. Conclusions
The proteasome has been implicated as a potential target for stimulation in a number of disease
states marked by protein accumulation. In this review, we discussed current methods of identifying
and evaluating stimulators of various isoforms of the proteasome, such as high-throughput biochemical
assays using ﬂuorogenic substrates, cellular studies of GFP-fusion proteins, and structural experiments
using AFM or cryo-EM. We also examined established methods of monitoring proteasome activity in
cells that have the possibility of being used to analyze small molecule stimulators, which includes
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cellular ﬂuorogenic or bioluminescent assays and using radio-labeled substrates to assess degradation
by the proteasome.
Though the methods described here are eﬀective at identifying stimulators of the proteasome,
multiple assays are often required to (1) validate the small molecule as a proteasome stimulator,
(2) determine the general mechanism of stimulation, and (3) assess the eﬃciency of the stimulator in
cell models. The cellular assays used to this point are not high-throughput, requiring a signiﬁcant
amount of time and materials. It is, therefore, important to develop and apply more high-throughput
cellular methods to identify and assess proteasome stimulators to directly evaluate their eﬀectiveness
in cell models. This would streamline the process of determining the therapeutic potential of a small
molecule stimulator toward a protein accumulation disease.
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